



UNITED STATES PATENT AND TRADEMARK OFFICE

Handwritten mark

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/378,759	08/23/1999	GARY M. FOX	06843.0027-0	9481
22852	7590	09/21/2004	EXAMINER	
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP 1300 I STREET, NW WASHINGTON, DC 20005			BRANNOCK, MICHAEL T	
			ART UNIT	PAPER NUMBER
			1646	

DATE MAILED: 09/21/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/378,759

Applicant(s)

FOX ET AL.

Examiner

Michael Brannock

Art Unit

1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on 01 July 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☐ Claim(s) 28,29,31,36-38,40,41 and 46-56 is/are pending in the application.
- 4a) Of the above claim(s) 28, 29, 31, 36, 37 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) 38,40,41 and 46-56 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1646

DETAILED ACTION

Status of Application: Claims and Amendments

Applicant is notified that the amendments put forth on 07/01/04 have been entered in full.

Response to Amendment

Applicant is notified that any outstanding rejection or objection that is not expressly maintained in this Office action has been withdrawn in view of Applicant's amendments.

New Rejections:

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 38, 40, 41, 46-56 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pasquale EB, Cell Regulation 2(7)523-534, 1991 in view of U.S. Patent No: 4816567. As set forth previously, chicken Cck5 and the instant SEQ ID NO: 11 are 95% identical, thus the skilled artisan would expect that most of the antibodies produced by raising against Cck5 would be indistinguishable from most of those obtained by raising against SEQ ID NO: 11. Thus the claims are product by process claims, wherein the manner of making the product does not place patentable weight on the product made. "A product made by any other process renders a product-by-process claim unpatentable. See *In re Marosi*, 710 F.2d 799, 218 USPQ 289 (Fed. Cir. 1983) and *In re Thorpe*, 777 F.2d 695, 227 USPQ 964 (Fed. Cir. 1985). "

Art Unit: 1646

Whereas Pasquale teach only polyclonal antibodies, as set forth previously, 4816567 teaches that in the art of antibody production, monoclonal antibodies are generally preferred to polyclonal antibodies (col 2, line 17), while CDR grafted and otherwise chimeric antibodies are more preferred, see col 2, lines 40-65 and cols 15 D.6 and D.7).

Therefore, it would be obvious to one of ordinary skill in the art at the time the invention was made, with reasonable expectation of success, to make a monoclonal, chimeric, or CDR grafted antibodies according to U.S. Patent No: 4816567 when practicing the invention of Pasquale EB. The motivation to do so is provided by U.S. Patent No: 4816567 wherein in is indicated that in the art of antibody production, monoclonal antibodies are generally preferred to polyclonal antibodies (col 2, line 17), while CDR grafted and otherwise chimeric antibodies are more preferred, see col 2, lines 40-65 and cols 15 D.6 and D.7).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Brannock, Ph.D., whose telephone number is (571) 272-0869. The examiner can normally be reached on Mondays through Fridays from 10:00 a.m. to 4:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback, Ph.D., can be reached at (571) 272-0961.

Official papers filed by fax should be directed to (703) 872-9306. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294.

Application/Control Number: 09/378,759

Page 4


Art Unit: 1646

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

MB



September 17, 2004



ELIZABETH KEMMERER
PRIMARY EXAMINER